Cipla enters joint venture with Cooper Pharma and the Pharmaceutical Institute in Morocco

Published: 10-Feb-2015
Finance

Cipla (EU) Limited will focus on respiratory and neurology portfolio and set up manufacturing plant in the country


Indian pharmaceutical company Cipla has formed a joint venture (JV) agreement with Morocco-based Societe Marocaine De Cooperation Pharmaceutique (Cooper Pharma) and the Pharmaceutical Institute (PHI) to enhance its presence in the region.

Cipla (EU) Limited, a wholly owned subsidiary of the Mumbai-based firm, has signed the JV with the Moroccan companies.

The JV will initially focus on respiratory and neurology products and will also invest in setting up a manufacturing facility in Morocco, the company said.

Cipla (EU) Limited will hold a 60% stake in the JV, while Cooper Pharma and PHI shall together hold 40%. Cipla (EU) Limited will invest up to US$15m in the JV.

Subhanu Saxena, Cipla's MD and Global CEO, said: 'Morocco is an attractive pharmaceutical market in the African continent. This JV is aimed to strengthen Cipla’s presence in Morocco, which is in-line with our global growth strategy to build front-end presence in key markets. Cipla has enjoyed a long-standing business relationship with Cooper Pharma and PHI for over a decade and this JV will further strengthen Cipla’s relationship.'

  • Companies:
  • Cipla
See more

You may also like

Finance

Cipla and Kemwell announce joint venture for biosimilars

Read more
The venture will leverage the companies’ combined strengths in product development, clinical development, regulatory filings, manufacturing and commercialisation

Trending Articles

  1. Small molecules: big market opportunities The rapid rise of biologic drugs in recent years has been accompanied by a market narrative that suggests that innovation and new treatments will be fuelled by breakthroughs in this area, leading to a decline in the small molecule pipeline. This is far from true, notes Kevin Cook, Chief Executive Officer at Sterling Pharma Solutions; both are increasing and small molecule drugs continue to be a mainstay of many drug development portfolios
  2. Policy vacuum risks UK becoming a medicines supply backwater The UK becoming a "backwater" supply marker could jeopardise £18bn of NHS savings from newly off-patented drugs during the next five years
  3. Lonza appoints President of Capsules and Health Ingredients Christian Seufert joins from BASF, where he has worked for the last 20 years. Most recently, he held the role of Senior VP for the Global Business Unit Pharma Solutions
  4. You need to be a subscriber to read this article.
    Click here to find out more.
    The pros and cons of distribution agreements For life sciences companies seeking to break into overseas markets, distribution agreements are central to success
  5. AstraZeneca to stop production of Pulmicort pMDI Agreements with SkyePharma expected to be terminated

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Finance

Cipla and Kemwell announce joint venture for biosimilars

The venture will leverage the companies’ combined strengths in product development, clinical development, regulatory filings, manufacturing and commercialisation
Ingredients

Cipla signs COVID-19 licensing agreement with Gilead Sciences

Indian Cipla will be permitted to manufacture US-based Gilead’s API and finished product of Remdesivir and market it in 127 countries including India and South Africa under its own brand name
Research & Development

Indian Cipla funnels $1 million into facility in Minsk

The facility will be used to localise the production of innovative solid medicines in Belarus
Finance

Cipla to step up efforts in US market

Competition heating up, with the US Food and Drug Association approving rival drugs, which could eat away at Cipla's market share in the generic business.
Finance

Cipla to acquire two US generics companies for $550m

Acquisition of InvaGen gives Cipla scale in the US generics market with a strong manufacturing and R&D base, access to a broad product portfolio and a strong customer base
Finance

Operating margins expected to grow by 28% year-on-year for Indian pharma firms

Most are focusing on niche products in the US
Finance

Indian drug companies expected to sustain margin improvement

India business is bouncing back aided by favourable exchange rates
Subscribe now